 | • レポートコード：MRC2302F0122 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、250ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に1424.7億ドルであった世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模が、2022年に1553.1億ドルになり、2027年まで年平均9.18%で成長して2414.1億ドルまで拡大すると予測しています。本レポートは、医薬品有効成分におけるCDMO（医薬品開発製造受託機関）の世界市場について調査し、市場の動向を明らかにした資料であり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療薬別（ジェネリック医薬品、革新的医薬品）分析、合成別（バイオテクノロジー、合成）分析、製品別（抗体薬物複合体（ADC）、高活性医薬品成分（HP-API）、従来型医薬品原薬（Traditional API））分析、ワークフロー別（臨床、商業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など以下の構成でまとめています。また、AbbVie, Inc.、Albemarle Corporation、Boehringer Ingelheim、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company、Cambrex、Catalent、Cipla, Inc.、Corden Pharma.、Lonza、Merck & Co., Inc.、Piramal Pharma Solutions、ReciPharm、Samsung Biologics、Siegfried、Teva Pharmaceutical Industries Ltd.、ThermoFisher Pantheonなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模：治療薬別 - ジェネリック医薬品の市場規模 - 革新的医薬品の市場規模 ・世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模：合成別 - バイオテクノロジーにおける市場規模 - 合成における市場規模 ・世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模：製品別 - 抗体薬物複合体（ADC）の市場規模 - 高活性医薬品成分（HP-API）の市場規模 - 従来型医薬品原薬（Traditional API）の市場規模 ・世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模：ワークフロー別 - 臨床における市場規模 - 商業における市場規模 ・世界の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模：地域別 - 南北アメリカの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 アメリカの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 カナダの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 ブラジルの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 … - アジア太平洋の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 日本の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 中国の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 インドの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 韓国の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 台湾の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 … - ヨーロッパ/中東/アフリカの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 イギリスの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 ドイツの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 フランスの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 ロシアの医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 … - その他地域の医薬品有効成分におけるCDMO（医薬品開発製造受託機関）市場規模 ・競争状況 ・企業情報 |
The Global Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 142.47 billion in 2021 and expected to reach USD 155.31 billion in 2022, and is projected to grow at a CAGR 9.18% to reach USD 241.41 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Active Pharmaceutical Ingredients CDMO to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Generics and Innovative.
Based on Synthesis, the market was studied across Biotech and Synthetic.
Based on Product, the market was studied across Antibody Drug Conjugate (ADC), Highly Potent Active Pharmaceutical Ingredient (HP-API), and Traditional Active Pharmaceutical Ingredient (Traditional API).
Based on Workflow, the market was studied across Clinical and Commercial.
Based on Application, the market was studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Active Pharmaceutical Ingredients CDMO market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Active Pharmaceutical Ingredients CDMO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Active Pharmaceutical Ingredients CDMO Market, including AbbVie, Inc., Albemarle Corporation, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cambrex, Catalent, Cipla, Inc., Corden Pharma., Lonza, Merck & Co., Inc., Piramal Pharma Solutions, ReciPharm, Samsung Biologics, Siegfried, Teva Pharmaceutical Industries Ltd., and ThermoFisher Pantheon.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Active Pharmaceutical Ingredients CDMO Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Active Pharmaceutical Ingredients CDMO Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Pharmaceutical Ingredients CDMO Market?
4. What is the competitive strategic window for opportunities in the Global Active Pharmaceutical Ingredients CDMO Market?
5. What are the technology trends and regulatory frameworks in the Global Active Pharmaceutical Ingredients CDMO Market?
6. What is the market share of the leading vendors in the Global Active Pharmaceutical Ingredients CDMO Market?
7. What modes and strategic moves are considered suitable for entering the Global Active Pharmaceutical Ingredients CDMO Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing pharmaceutical R&D investment
5.1.1.2. Rising demand for generic drugs and biologic innovation
5.1.1.3. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
5.1.2. Restraints
5.1.2.1. Compliance issues while outsourcing
5.1.3. Opportunities
5.1.3.1. Expanding consumption of biopharmaceuticals
5.1.3.2. Rising prevalence of cancer and increasing sophistication in oncology drug research
5.1.4. Challenges
5.1.4.1. Stringent government regulations
5.2. Cumulative Impact of COVID-19
6. Active Pharmaceutical Ingredients CDMO Market, by Drug
6.1. Introduction
6.2. Generics
6.3. Innovative
7. Active Pharmaceutical Ingredients CDMO Market, by Synthesis
7.1. Introduction
7.2. Biotech
7.3. Synthetic
8. Active Pharmaceutical Ingredients CDMO Market, by Product
8.1. Introduction
8.2. Antibody Drug Conjugate (ADC)
8.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
8.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
9. Active Pharmaceutical Ingredients CDMO Market, by Workflow
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Active Pharmaceutical Ingredients CDMO Market, by Application
10.1. Introduction
10.2. Cardiovascular
10.3. Diabetes
10.4. Glaucoma
10.5. Hormonal
10.6. Oncology
11. Americas Active Pharmaceutical Ingredients CDMO Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AbbVie, Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Albemarle Corporation
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Boehringer Ingelheim
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Boehringer Ingelheim International GmbH
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Bristol-Myers Squibb Company
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Cambrex
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Catalent
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Cipla, Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Corden Pharma.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Lonza
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Merck & Co., Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Piramal Pharma Solutions
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. ReciPharm
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Samsung Biologics
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Siegfried
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Teva Pharmaceutical Industries Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. ThermoFisher Pantheon
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing